Open-Angle Glaucoma Clinical Research Pipeline Broadens With 20+ Novel Therapies, Reports DelveInsight | FDA Clearances, Drugs, Treatment Options, Key Players

Open-Angle Glaucoma Clinical Trials

Based on DelveInsight’s evaluation, the global Open-Angle Glaucoma development pipeline comprises over 18 companies working on more than 20 therapeutic candidates. The analysis spans ongoing clinical trials, treatment strategies, mechanisms of action, delivery routes, and major milestones across development stages.

The “Open Angle Glaucoma Pipeline Insight” report delivers an in-depth assessment of the existing clinical development landscape while highlighting future expansion opportunities within the Open-Angle Glaucoma market.

This pipeline analysis provides an extensive commercial and clinical review of therapies ranging from preclinical research to marketed drugs. It includes comprehensive product profiles covering mechanisms of action, clinical outcomes, regulatory progress, and current development initiatives such as innovation advancements, strategic collaborations, mergers and acquisitions, funding activities, and special regulatory designations.

Request a Sample Report here @ Open Angle Glaucoma Pipeline Outlook

Key Highlights from the Open Angle Glaucoma Pipeline Report

• Companies worldwide are actively engaged in advancing innovative Open-Angle Glaucoma therapies, demonstrating notable progress over recent years.
• Major players developing treatments for Open-Angle Glaucoma include Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others.
• Promising emerging therapies such as TO-O-1001, BTQ-1902, NCX 470, and additional candidates are anticipated to significantly influence the Open-Angle Glaucoma treatment landscape in the near future.
• In April 2025, Perfuse Therapeutics, Inc. released results from a Phase 1/2a clinical study assessing the safety, tolerability, and pharmacodynamic effects of a single dose of the PER-001 intravitreal implant in patients with Open-Angle Glaucoma.
• In March 2025, Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX) announced that the final patient completed their last visit in the Whistler Phase 3b trial, which evaluated NCX 470’s dual nitric oxide–prostaglandin analog mechanism for lowering intraocular pressure (IOP). NCX 470, Nicox’s lead asset, is an advanced nitric oxide–donating bimatoprost eye drop currently in Phase III development for Open-Angle Glaucoma and ocular hypertension.
• In February 2025, Qlaris Bio, Inc. reported positive topline data from two U.S.-based Phase II trials—Osprey and Apteryx—investigating QLS-111 in patients with primary Open-Angle Glaucoma and ocular hypertension. Both studies successfully met their primary and secondary endpoints.
• In January 2025, Glaukos Corporation (NYSE: GKOS), a leader in glaucoma pharmaceuticals and medical technologies, initiated a Phase 2b/3 clinical program for iDose TREX, its next-generation sustained-release therapy. The platform retains the original iDose TR design while offering nearly twice the drug payload.
• In October 2024, during the American Academy of Ophthalmology (AAO) 2024 Annual Meeting in Chicago, results from a Phase II safety study of Neurotech Pharmaceuticals’ NT-501 encapsulated cell therapy were presented. The CNTF-secreting implant demonstrated favorable tolerability and no serious adverse events in patients with primary Open-Angle Glaucoma, as presented by Alexandria M. Dominguez, MS, from Stanford University’s Byers Eye Institute.
• In March 2024, MediPrint® Ophthalmics announced the successful completion of its Phase 2b glaucoma clinical trial, reporting positive outcomes.
• In February 2024, Skye Bioscience completed patient enrollment for its Phase 2a trial evaluating SBI-100 ophthalmic emulsion in glaucoma and ocular hypertension.
• At ASCRS 2024, data from a Phase II study investigating a travoprost intracameral implant for Open-Angle Glaucoma and ocular hypertension were presented.

Open-Angle Glaucoma Overview

Open-Angle Glaucoma is the most prevalent type of glaucoma and is marked by gradual optic nerve damage due to impaired aqueous humor drainage through the trabecular meshwork. The disease progresses slowly and often remains asymptomatic until advanced vision loss occurs, underscoring the importance of early diagnosis. Common risk factors include advancing age, genetic predisposition, elevated intraocular pressure, and comorbid conditions such as diabetes and hypertension. Diagnosis typically involves optic nerve imaging, visual field assessments, and intraocular pressure measurement. Treatment strategies focus on lowering IOP through pharmacological therapies, laser interventions, or surgical procedures to slow disease progression and preserve visual function.

Get a Free Sample PDF Report to learn more about the Open Angle Glaucoma Pipeline Therapeutic Assessment – Open Angle Glaucoma Treatment Market

Open-Angle Glaucoma Routes of Administration

The pipeline report evaluates therapeutic candidates based on their routes of administration, which include:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Open-Angle Glaucoma Molecule Types

Pipeline therapies are categorized according to molecular classification, including:

• Monoclonal antibodies
• Small molecules
• Peptides

Open-Angle Glaucoma Pipeline Therapeutic Evaluation

• Assessment by Product Type
• Analysis by Development Stage and Product Type
• Evaluation by Route of Administration
• Stage-wise Analysis by Route of Administration
• Assessment by Molecule Type
• Stage-wise Molecule Type Evaluation

DelveInsight’s Open-Angle Glaucoma report analyzes more than 20 pipeline assets across various stages of development, including:

• Late-stage candidates (Phase III)
• Mid-stage candidates (Phase II)
• Early-stage candidates (Phase I)
• Preclinical and discovery-stage programs
• Discontinued or inactive assets

]

The report provides detailed insights into individual pipeline products. Download the Open-Angle Glaucoma Pipeline Report to gain a deeper understanding of emerging therapies and treatment innovations in the Open-Angle Glaucoma space.

Further Open Angle Glaucoma product details are provided in the report. Download the Open Angle Glaucoma pipeline report to learn more about the emerging Open Angle Glaucoma therapies- Open Angle Glaucoma Drugs and Therapies

Open-Angle Glaucoma Pipeline Analysis

The pipeline report delivers comprehensive insights covering:

• An in-depth review of companies developing Open-Angle Glaucoma therapies, along with the number and types of assets in their pipelines.
• Stage-wise analysis of therapeutic candidates spanning early, mid, and late development phases.
• Identification of major stakeholders involved in targeted therapy development, including active and discontinued programs.
• Classification of pipeline drugs by development stage, administration route, therapeutic target, monotherapy or combination usage, mechanism of action, and molecular class.
• A detailed evaluation of collaborative efforts, including industry partnerships, academic collaborations, licensing agreements, and funding activities supporting pipeline advancement.

Download Sample PDF Report to know more about Open Angle Glaucoma drugs and therapies- Open Angle Glaucoma Clinical Trials and FDA Approvals

Scope of the Open-Angle Glaucoma Pipeline Drug Insight

• Geographic Coverage: Global
• Key Companies: Nicox Ophthalmics (EPA: COX), Betaliq, Inc. (Private), Qlaris Bio (Private), Aerpio Pharmaceuticals (OTC: ARPO), Theratocular Biotek (Private), PolyActiva Pty Ltd. (Private), Whitecap Biosciences (Private), JeniVision (Private), EMS (Private), and others
• Key Therapies: TO-O-1001, BTQ-1902, NCX 470, and additional candidates
• Therapeutic Assessment: Marketed and emerging Open-Angle Glaucoma treatments
• Market Dynamics: Key drivers and challenges impacting the Open-Angle Glaucoma market

Request for Sample PDF Report for Open Angle Glaucoma Pipeline Assessment and clinical trials – Open Angle Glaucoma Therapeutics Market

Table of Contents

1. Introduction to the Open-Angle Glaucoma Report
2. Executive Summary
3. Disease Overview
4. In-depth Commercial and Analytical Perspective
5. Pipeline Therapeutics Overview
6. Late-Stage Products (Phase II/III)
7. Mid-Stage Products (Phase II)
8. Early-Stage Products (Phase I)
9. Preclinical Pipeline Assets
10. Therapeutic Assessment
11. Inactive and Discontinued Products
12. Company–University Collaboration and Licensing Analysis
13. Key Companies
14. Leading Products
15. Unmet Medical Needs
16. Market Drivers and Barriers
17. Future Outlook and Conclusions
18. Analyst Perspectives
19. Appendix
20. About DelveInsight

About DelveInsight

DelveInsight is a prominent healthcare consulting and market research firm dedicated exclusively to the life sciences sector. The company assists pharmaceutical and biotechnology organizations with end-to-end strategic solutions aimed at enhancing operational performance. DelveInsight’s healthcare consulting services enable robust market analysis, support strategic decision-making, and help organizations accelerate growth while effectively navigating industry challenges.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/partner-identification-services